Additionally, it was found that when administered with LIPU/MB, doxorubicin’s efficacy surpassed simple drug delivery; it significantly modulated the TME, potentially improving the presentation of tumor antigens to T cells, thereby enhancing the efficacy of T cell-based immunotherapy (including PD-1 blockade). This evidence concerns the gene RPL17 and neoplasm.